Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–45
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Female subjects of age 18 to 45 years, inclusive, who are healthy, non-pregnant, not planning pregnancy within the study period
Willing to use a highly effective method of birth control, ie, double barrier method contraception (condom and diaphragm with spermicide) from the first day of Period 1 until 28 days after the last dose
Body weight of at least 50 kg and body mass index (BMI) between 18 and 30 kg/m2 inclusive
Two negative pregnancy tests at least 7 days apart
You may not be if
History of any clinically significant disease or disorder
History or presence of Gastrointestinal, hepatic, or renal disease
Any condition listed as a contraindication in the Microgynon® 30 labelling
Absolute neutrophil count less than 2.5 x 109/L.
Clareo Health | Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects
